NOV 08, 2013 12:00 PM PST

Childhood cancer with various genomic assay including whole genome sequencing

Speaker
  • Scientific Projects Manager, TARGET, NCI Office of Cancer Genomics
    Biography
      Dr. Guidry Auvil is a scientific program officer overseeing large-scale genomics efforts within the Office of Cancer Genomics at the National Cancer Institute.  She completed her doctoral work in the Biomedical Sciences program and received her PhD in tumor biology at Georgetown University.  In graduate school, Dr. Guidry Auvil studied the effects of cellular adhesion molecules on breast cancer bone metastases and holds a patent for a viable small molecule inhibitor of cadherin-11, which is currently being tested for various therapeutic applications. She also has a background in clinical and psychosocial research and project management in both the biotechnology and healthcare sectors. Dr. Guidry Auvil now manages the NCI pediatric cancer genomics initiative, Therapeutically Applicable Research to Generate Effective Treatments (TARGET).    
      <br />

    Abstract

    The NCI's Therapeutically Applicable Research to Generate Effective Treatments (TARGET) is a comprehensive genomic characterization initiative to determine the molecular changes that drive the development and progression of certain childhood cancers. TARGET seeks to improve treatment of these cancers through identification of valid molecular targets, in and across each disease, and ultimately lead to the rapid development of novel, more effective therapies. The TARGET projects include primarily high-risk for relapse cases. Most TARGET disease groups also have relapse samples available for study, thereby allowing the determination of changes that occur during the disease progression. To accelerate translation into the clinic, TARGET data is readily available to the research community for further investigation. There are currently around 2,000 TARGET BAM files from next generation platforms currently available to investigators, and additional sequencing files are regularly being submitted to expand the TARGET datasets. All TARGET cases have either whole genome or exome sequencing of matched tumor and normal pairs (relapse sample when available), and transcriptome sequences exist for most TARGET cases as well. In addition, all TARGET cases have clinical annotation, array-based gene expression and copy number data available to researchers, most also have methylation profiles, to allow for a more complete understanding of the molecular basis of these childhood cancers. Some projects have further included miRNA characterization data as well.


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    NOV 10, 2020 7:00 AM PST
    C.E. CREDITS
    NOV 10, 2020 7:00 AM PST
    DATE: November 10, 2020 TIME: 7:00am PDT, 10:00am EDT Automation can provide tremendous benefits such as increased pipetting precision and accuracy, productivity, and throughput. Numerous wo...
    DEC 03, 2020 4:30 PM PST
    C.E. CREDITS
    DEC 03, 2020 4:30 PM PST
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    NOV 08, 2013 12:00 PM PST

    Childhood cancer with various genomic assay including whole genome sequencing


    Specialty

    Antibodies

    Immunology

    Dna Sequencing

    Clinical Diagnostics

    Bioinformatics

    Gene Expression

    Dna

    Cancer

    Gene Sequencing

    Cell Culture

    Biotechnology

    Cognitive Neuroscience

    Brain Health

    Virology

    Genetics

    Geography

    Europe100%

    Registration Source

    Website Visitors100%

    Job Title

    Student100%

    Organization

    Academic Institution50%

    Retired50%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more